Subgroup Analyses in the Treatment of Diabetic Nephropathy: A Meta-Analysis
DOI:
https://doi.org/10.61882/ijkd.19.3.141Keywords:
Meta-analysis, Diabetic nephropathy, Diabetic kidney disease, Subgroup analysisAbstract
Introduction. This meta-analysis synthesizes and evaluates treatments for diabetic nephropathy, focusing on subgroup analyses to understand efficacy variations across diverse patient demographics and disease characteristics, thereby advancing personalized healthcare in diabetic kidney disease.
Methods. Adhering to PRISMA guidelines, a thorough literature search across PubMed, NCBI, and Web of Science initially identified 904 studies spanning from 2015 to 2023. A meticulous screening process, involving the review of titles and abstracts and the application of stringent inclusion and exclusion criteria, refined the selection to six studies. These studies were selected for their comprehensive focus on diabetic nephropathy, availability of odds ratio data, and detailed subgroup analyses. Statistical synthesis was conducted using a random-effects model, and heterogeneity was assessed using the I² statistic.
Results. Analysis of the selected studies revealed significant heterogeneity in treatment effectiveness related to patient demographics, nephropathy stages, genotypes, and other disease-specific characteristics. The overall estimated odds ratio (OR) for treatment efficacy was 2.7 (95% CI: 1.8-3.6), indicating a moderate effect size. This variation highlighted the complex interplay of genetic, environmental, and lifestyle factors in nephropathy treatment outcomes. The study also delved into the mechanistic aspects of treatment interactions with diverse nephropathy subtypes, thereby offering a deeper understanding of the efficacy of treatments within specific patient categories.
Conclusions. The study underscores the critical need for personalized treatment strategies in diabetic nephropathy, providing valuable insights for healthcare professionals. It advocates for tailoring treatments to individual patient profiles to optimize outcomes, enhancing patient care quality. These findings reinforce the value of subgroup-based approaches and support evidence-based, patient-centric management in diabetic kidney disease.
Downloads
References
Sagoo MK, Gnudi L. Diabetic nephropathy: an overview. Diabetic Nephropathy: Methods and Protocols 2020: 3-7.
Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. Journal of the American society of nephrology 2005; 16(3_suppl_1): S30-S3.
Mooyaart A, Valk E, Van Es L, et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia 2011; 54: 544-53.
Wagnew F, Eshetie S, Kibret GD, et al. Diabetic nephropathy and hypertension in diabetes patients of sub-Saharan countries: a systematic review and meta-analysis. BMC research notes 2018; 11: 1-7.
Birck R, Krzossok S, Markowetz F, Schnülle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. The Lancet 2003; 362(9384): 598-603.
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews 2015; 4: 1-9.
Sarkis-Onofre R, Catalá-López F, Aromataris E, Lockwood C. How to properly use the PRISMA Statement. Systematic Reviews 2021; 10(1): 1-3.
Huang Y, Wan C, Wu G. Acute kidney injury after a stroke: A PRISMA‐compliant meta‐analysis. Brain and Behavior 2020; 10(9): e01722.
An X, Xu Y, Gui D. Combination of Astragalus membranaceus and Panax notoginseng as Main Components in the Treatment of Diabetic Nephropathy: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine 2023; 2023.
Lee EY, Lee Y-h, Kim SH, et al. Association between heme oxygenase-1 promoter polymorphisms and the development of albuminuria in type 2 diabetes: a case–control study. Medicine 2015; 94(43): e1825.
Dai H, Zhang H, He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Scientific reports 2015; 5(1): 8803.
Del Rio-Pertuz G, Leelaviwat N, Mekraksakit P, Benjanuwattra J, Nugent K, Ansari MM. Association between elevated CHA2DS2-VASC score and contrast-induced nephropathy among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Acta Cardiologica 2023; 78(8): 922-9.
Rauen T, Fitzner C, Eitner F, et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. Journal of the American Society of Nephrology 2018; 29(1): 317-25.
Xie J, Lv J, Wang W, et al. Kidney failure risk prediction equations in IgA nephropathy: a multicenter risk assessment study in Chinese patients. American Journal of Kidney Diseases 2018; 72(3): 371-80.
Del Rio-Pertuz G, Leelaviwat N, Mekraksakit P, Benjanuwattra J, Nugent K, Ansari MM. Association between elevated CHA2DS2-VASC score and contrast-induced nephropathy among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Acta Cardiologica 2023: 1-8.
Rauen T, Fitzner C, Eitner F, et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. Journal of the American Society of Nephrology: JASN 2018; 29(1): 317.
